Horizon 1 1 17 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES Human Vaccines and Immunotherapeutics 3907-3912 Vaccine trial COVID-19 Senegal acceptability participation SENEGAL 2021 fdi:010082596 ENG Human Vaccines and Immunotherapeutics 2164-5515 ISI:000674817900001 11 10.1080/21645515.2021.1951097 https://www.documentation.ird.fr/hor/fdi:010082596 https://horizon.documentation.ird.fr/exl-doc/pleins_textes/2022-09/010082596.pdf 17 Horizon (IRD) This research aims to understand the level and determinants of people's willingness to participate in a vaccine trial for COVID-19 in Senegal. We conducted a telephone survey among a marginal quota sample of 607 people over 18 years of age. Only 44.3% of the participants wanted to participate in a vaccine trial for COVID-19, with females intending to participate more than males (AOR = 1.82, 95% CI [1.22-2.72]). Participants who intended to be vaccinated against COVID-19 (AOR = 6.48, 95% CI [4.12-10.4]) and who thought that being infected with the coronavirus would have a significant impact on their health (AOR = 2.34, 95% CI [1.57, 3.51]) were more likely to agree to take part in the COVID-19 vaccine trial. Confidence in the vaccine, health personnel, and the government in the fight against the pandemic are key factors in participants' willingness to participate in a vaccine trial in Senegal. 052 ; 050 ; 056 UR196 / UR215 Sénégal